Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Detection Technology of Peripheral Blood ctDNA Based on CRISPR/Cas and Gold Nanoparticles

NCT07916636 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07916636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Detection Technology of Peripheral Blood ctDNA Based on CRISPR/Cas and Gold Nanoparticles
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Observational
Overall status
Not yet recruiting
Start date
January 21, 2027
Completion date
December 1, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, circulating tumor dna detection

Arms

As registered; 2 arms.

  • Cancer patients

    Patients with BRCA1-related tumors (e.g., breast, ovarian, or prostate cancer) enrolled at participating hospitals. Approximately 3 mL of EDTA-anticoagulated peripheral blood is collected from each participant. Each sample is tested by both the investigational CRISPR/Cas12a-gold nanoparticle ctDNA detection method and next-generation sequencing (NGS, the gold standard reference), and the results of the two methods are compared to evaluate diagnostic accuracy and sensitivity.

  • Healthy Volunteers

    Healthy adults without a history of cancer, enrolled as the control group for specificity assessment. Approximately 3 mL of EDTA-anticoagulated peripheral blood is collected from each participant and tested by the CRISPR/Cas12a-gold nanoparticle method to determine the false positive rate.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Diagnostic accuracy of the CRISPR/Cas12a-gold nanoparticle ctDNA test compared with NGS through study completion, an average of 1 year

    The agreement between the CRISPR/Cas12a-gold nanoparticle ctDNA detection method and next-generation sequencing (NGS, the gold standard reference) will be evaluated in tumor patient samples. Diagnostic accuracy is measured by the Kappa coefficient of concordance between the two methods, with Kappa ≥0.85 considered excellent agreement. Sensitivity (detection positive rate of 1 pM, 0.5 pM, and 0.1 pM target ctDNA samples; ≥95% considered qualified) and specificity (false positive rate in 50 healthy volunteer samples; ≤5% considered qualified) will also be assessed.

Lead sponsor's other trials

The First Affiliated Hospital of Zhengzhou University, most recent start first.

Similar trials

Same condition (Neoplasms) and phase, most recent start first.